Evidence map›Paper›PMID 38248371›Full record

ArticleDiseases (Basel, Switzerland)2024

The Screening and Mechanism of Influenza-Virus Sensitive MDCK Cell Lines for Influenza Vaccine Production.

Zhaona Yang, Shouzhi Yu, Ying Xu, Yuxiu Zhao, Lili Li, Jingjie Sun, Xin Wang, Yancen Guo, Yuntao Zhang

Open access · goldAbstract read
In one paragraph

Article in Diseases (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Zhaona YangBeijing Institute of Biological Products Company Limited, Beijing 100176, China.
Shouzhi YuBeijing Institute of Biological Products Company Limited, Beijing 100176, China.
Ying XuBeijing Institute of Biological Products Company Limited, Beijing 100176, China.
Yuxiu ZhaoBeijing Institute of Biological Products Company Limited, Beijing 100176, China.
Lili LiBeijing Institute of Biological Products Company Limited, Beijing 100176, China.
Jingjie SunBeijing Institute of Biological Products Company Limited, Beijing 100176, China.
Xin WangBeijing Institute of Biological Products Company Limited, Beijing 100176, China.
Yancen GuoBeijing Institute of Biological Products Company Limited, Beijing 100176, China.
Yuntao ZhangBeijing Institute of Biological Products Company Limited, Beijing 100176, China.
National Vaccine and Serum Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza is a potentially fatal acute respiratory viral disease caused by the influenza virus. Influenza viruses vary in antigenicity and spread rapidly, resulting in seasonal epidemics. Vaccination is the most effective strategy for lowering the incidence and fatality rates of influenza-related disorders, and it is also an important method for reducing seasonal influenza infections. Mammalian Madin-Darby canine kidney (MDCK) cell lines are recommended for influenza virus growth, and such cell lines have been utilized in several commercial influenza vaccine productions. The limit dilution approach was used to screen ATCC-MDCK cell line subcellular strains that are especially sensitive to H1N1, H3N2, BV, and BY influenza viruses to increase virus production, and research on influenza virus culture media was performed to support influenza virus vaccine development. We also used RNA sequencing to identify differentially expressed genes and a GSEA analysis to determine the biological mechanisms underlying the various levels of susceptibility of cells to influenza viruses. MDCK cell subline 2B6 can be cultured to increase titer and the production of the H1N1, H3N2, BV, and BY influenza viruses. MDCK-2B6 has a significantly enriched and activated in ECM receptor interaction, JAK-STAT signaling, and cytokine receptor interaction signaling pathways, which may result in increased cellular susceptibility and cell proliferation activity to influenza viruses, promote viral adsorption and replication, and elevate viral production, ultimately. The study revealed that MDCK-2B6 can increase the influenza virus titer and yield in vaccine production by increasing cell sensitivity and enhancing proliferative activity.

Indexed as

BVBYH1N1H3N2influenza vaccineinfluenza virusMDCK

Identifiers

PMID38248371
PMCPMC10814076
OpenAlexW4390695710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.